Details for: VELCADE
Company: JANSSEN INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02262452 | VELCADE | BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) | 3.5 MG / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
| 02262452 | VELCADE | BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) | 3.5 MG / VIAL | POWDER FOR SOLUTION | SUBCUTANEOUS |
Summary Reports
Summary Basis of Decision
Summary Safety Review - Bortezomib (VELCADE and generics) - Assessing the Potential Risk of Flesh-Eating Disease (Necrotizing Fasciitis)
Summary Safety Review - Bortezomib (VELCADE and Generics) - Assessing a Potential Link with Flesh-Eating Disease (Necrotising Fasciitis)
Summary Safety Review - Bortezomib (VELCADE and generics) - Assessing the Potential Risk of Flesh-Eating Disease (Necrotizing Fasciitis)
Summary Safety Review - Bortezomib (VELCADE and Generics) - Assessing a Potential Link with Flesh-Eating Disease (Necrotising Fasciitis)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.